SCHEMBL2363784

SCHEMBL2363784

Cc1sc(NC(=O)c2ccc(N3CCN(S(=O)(=O)c4ccccc4)CC3)nc2)nc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.57
HPGD P15428 6/20 0.57
KMT2A Q03164 6/20 0.57
MAPT P10636 7/20 0.56
MEN1 O00255 5/20 0.54
HTT P42858 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
KDM4E B2RXH2 4/20 0.53
LMNA P02545 3/20 0.53
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ADORA3 P0DMS8 4/20 0.53
POLB P06746 1/20 0.53
HDAC1 Q13547 3/20 0.47
KCNH2 Q12809 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309522 0.87 ALDH1A1 (0.59) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL2363710 0.87 ALDH1A1 (0.61) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL2304830 0.86 ALDH1A1 (0.58) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL3310436 0.85 ALDH1A1 (0.57) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL3311877 0.84 LMNA (0.58) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL2300926 0.84 ADORA3 (0.59) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL31162579 0.83 SMN1; SMN2 (0.80) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL2303642 0.82 ADORA3 (0.55) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL13328317 0.82 ADORA3 (0.61) SMN1; SMN2HPGDKMT2AMAPTMEN1
SCHEMBL3311857 0.82 ADORA3 (0.53) SMN1; SMN2HPGDKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 SMN1; SMN2 4749/4885HPGD 951/4885KMT2A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.